MARKET

PULM

PULM

Pulmatrix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8000
+0.0274
+3.55%
After Hours: 0.7801 -0.0199 -2.49% 18:25 09/17 EDT
OPEN
0.7600
PREV CLOSE
0.7726
HIGH
0.8000
LOW
0.7540
VOLUME
274.60K
TURNOVER
--
52 WEEK HIGH
3.040
52 WEEK LOW
0.7300
MARKET CAP
45.00M
P/E (TTM)
-1.4575
1D
5D
1M
3M
1Y
5Y
Pulmatrix On Aug. 17, Got Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
-Reuters 
Reuters  · 08/23 20:22
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
Earnings Beat: Pulmatrix, Inc. (NASDAQ:PULM) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Pulmatrix, Inc. ( NASDAQ:PULM ) defied analyst predictions to release its second-quarter results, which were ahead of...
Simply Wall St. · 08/14 07:57
Pulmatrix, Inc. (PULM) Reports Q2 Loss, Tops Revenue Estimates
Zacks.com · 08/10 14:25
BRIEF-Pulmatrix Reports Q2 Results
reuters.com · 08/10 13:14
Pulmatrix Q2 EPS $(0.07) Down From $(0.05) YoY, Sales $2.25M Down From $3.50M YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.07) per share. This is a 40 percent decrease over losses of $(0.05) per share from the same period last year. The company reported $2.25 million in sales this
Benzinga · 08/10 13:11
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9)
Benzinga · 08/10 11:55
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PULM. Analyze the recent business situations of Pulmatrix through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PULM stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 32
Institutional Holdings: 7.96M
% Owned: 14.16%
Shares Outstanding: 56.25M
TypeInstitutionsShares
Increased
8
1.22M
New
3
310.50K
Decreased
4
337.81K
Sold Out
9
310.69K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
Michael Higgins
President/Chief Executive Officer/Director
Teofilo Raad
Vice President - Finance
Michelle Siegert
Director
Anand Varadan
Independent Director
Richard Batycky
Independent Director
Todd Bazemore
Independent Director
Christopher Cabell
No Data
About PULM
Pulmatrix, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing inhaled therapies to address serious respiratory disease. The Company designs and develops inhaled therapeutic products based on its dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways. iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with a broad range of drug substances including small molecules and biologics. The Company’s therapeutic candidates are Pulmazole, PUR1800, PUR5700, PUR3000 and PUR4000.

Webull offers kinds of Pulmatrix Inc stock information, including NASDAQ:PULM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PULM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PULM stock methods without spending real money on the virtual paper trading platform.